Scientific deep-dive

Why Combination Therapy Fails in Practice

A pragmatic trial of combining two diabetes drugs found 53% filled the prescription against 84% on one drug, and half of those who filled later stopped one. The participants were insured.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

Guidelines increasingly suggest combining an SGLT2 inhibitor with a GLP-1 in type 2 diabetes. A pragmatic trial tried to test that in ordinary care and ran into something before it could measure any outcome: people did not fill the prescriptions. At four months, 84% of the single-drug group had filled against 53% of the combination group.[1]

What happened

Participants were randomized to monotherapy or dual therapy and followed for a median of ten months. The gap in fill rates narrowed over time but did not close, ending at 87% against 68% overall. Among those who did fill, 22% of the monotherapy group and 49% of the dual therapy group discontinued a study medication, mostly because of side effects.[1]

Half of the people who started two drugs stopped at least one of them. Quality-of-life scores showed no change in either group, which is unsurprising when so much of the intended treatment never happened.

Among those who filled, 49% of the dual therapy group stopped a study medication, against 22% of the single-drug group.

Why this population makes it worse, not better

The participants were insured, and the study team had actively worked to facilitate medication uptake during the feasibility phase.[1] These were not people who could not afford treatment, and the conditions were substantially better than average.

If half of an insured, supported, trial-enrolled population cannot sustain two drugs, the guideline describes a regimen that mostly does not survive contact with a pharmacy counter.

It fits a pattern we keep finding

Three separate measurements now point the same way: a large share of the lost effect sits in the gap between what is prescribed and what is taken.

  • Only 58% reach maintenance dosing and 21% never leave the starting dose, in UK primary care.
  • Discontinuation runs from 36.9% to 55.8% depending on drug and formulation, in the same dataset.
  • Half of combination starters stop one drug, here.

Trials report what happens to people who take the drug, and guidelines assume they do. Neither describes the ordinary experience, and the difference is large. Our piece on why real-world results differ from trial results covers the same gap from the other end.

Side effects were the stated reason for most discontinuation. Adding a second drug adds a second side-effect profile rather than averaging them, so a patient asked to take both has two sets of side effects to tolerate instead of one.

What to take from it

If a combination has been suggested to you, the useful questions are practical ones. What will this cost each month once both are running, which one do we stop first if the side effects are intolerable, and what does the plan look like if only one of them is sustainable?

It is a small, early report (173 participants in the feasibility phase of a larger trial), and it measured something that larger, cleaner trials systematically design out.

Frequently Asked Questions

This trial could not answer that, because too little of the treatment happened. At four months only 53% of the combination group had filled their prescriptions against 84% on a single drug, and half of those who filled later discontinued one.
Not primarily. The participants were insured and the study team had worked to facilitate uptake. Most discontinuation was attributed to side effects rather than affordability.
Adding a drug adds its side-effect profile rather than averaging it, so a patient on both has two sets of side effects to tolerate instead of one. The trial did not break the discontinuations down by side effect.
It means a guideline recommendation and what happens at a pharmacy counter are different things. Trials report outcomes in people who take the drug; this measured how many do.
What the monthly cost is with both running, which drug is stopped first if side effects become intolerable, and what the plan is if only one turns out to be sustainable.

References

  1. 1.Wexler DJ, Mayberry LS, Nelson LA, et al. Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial American Heart Journal. 2026. PMID: 41456635.

Every Other Week: Stretching the Interval

Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

5 min read

Many People Never Reach the Dose

Only 58% of people starting semaglutide reached the recommended maintenance dose after four weeks, and 21% stayed on the starting dose. More than half of oral semaglutide starters stopped altogether.

6 min read

A Pill to Hold What the Injection Lost

Daily oral orforglipron maintained 79.3% of weight already lost against 37.6% on placebo at a year in people coming off semaglutide, and 74.7% against 49.2% after tirzepatide. The trial had no arm that stayed on the injection, which is the question people actually have.

5 min read

GLP-1s, Travel and Time Zones

For a weekly injection, time zones barely matter: a week is 168 hours and an eight-hour shift is under 5% of it. The daily oral, anchored to waking rather than the clock, is the one that needs planning.

5 min read

Switching Between GLP-1 Drugs

No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.

5 min read

Losing Fast Early: What It Predicts

Rapid responders in SURMOUNT-5, those down 15% or more at week 24, reported more gastrointestinal side effects and completed treatment at a similar rate to everyone else. The likely explanation is that fast loss and nausea reflect the same underlying response.

5 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.1

Sesame Care

Oral orforglipron alongside the injectables

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

8.8

altRX

Compounded semaglutide from $89/month at the same price at every dose

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →